Important Innovations

  DAILY INNOVATION BRIEF                                                                                                          By Journalists Edward Kane & Maryanne Kane NEW, SMART CAR COMMUNICATIONS TECHNOLOGY                                                       Source:  Skoda                                                            ...

  DAILY INNOVATION BRIEF                                                                                                          By Journalists Edward Kane & Maryanne Kane NEW, SMART CAR COMMUNICATIONS TECHNOLOGY                                                                                                                    ...

  DAILY INNOVATION BRIEF                                                                                                          By Journalists Edward Kane & Maryanne Kane NEW LIFE SAVING CANCER & HEART DISEASE VACCINES                                                                           Source:  Stock Image Cambridge, MA based Moderna says it expects to offer new, lifesaving vaccines that prevent cancer, heart disease & other untreatable ...

    DAILY INNOVATION BRIEF                                                                                                          By Journalists Edward Kane & Maryanne Kane NEW LIFE SAVING CANCER & HEART DISEASE VACCINES                                                                                                                   S...

    FDA Approves Moderna COVID Vaccine                                                                                Source:  Stock COVID image FDA Okays Australia's Home Diagnostic Test For COVID The FDA has given emergency approval to Moderna's COVID vaccine, making it the second COVID vaccine, along with Pfizer's,  available in the US.  The vaccine is 95% effective and is available to adults, while trials are expanded for teenagers. Meanwhile, the Australian diagnostic test company Ellume has scored a big win.  The FDA has approved its over the counter, at home,  COVID-19 test.  This is the first COVID-19 test approved for use at home.  Ellume Home COVID Test The system uses a nasal swab to collect data...

  COVID Vaccines Very Close to Market                                             Source:  Moderna Hope For a COVID Weary World Moderna, headquartered in Cambridge, MA, is seeking US, EU and UK emergency authorization for their COVID vaccine.  The vaccine has proved to be 94% effective.  The company adds it has no serious side effects. Highly Effective More than 1.5 million people have died from COVID.  Moderna says the vaccine is 100% effective in preventing severe cases of COVID.  It also works across demographic groups, including age, gender, ethnicity and race. Second COVID Vaccine Close to Market This is the second vaccine that is now under review for emergency authorization.  The other vaccine was developed by Pfizer and its German biotech partner BioNTech.  That vaccine is 95%.  Both the Pfizer and the Moder...

  1st Pfizer/BioNTech COVID Vaccine,  Now Moderna Vaccine                                    Source: Moderna COVID Vaccine Moderna Vaccine is 94.5% Effective, Pfizer More than 90% More hope in the fight against the COVID-19 global pandemic.  Cambridge, MA based biotech Moderna reports that it has a COVID vaccine candidate that is 94.5% effective against the deadly virus .  COVID-19 has infected more than 55 million people and taken more than 1.3 million lives globally as of today.  Pfizer/Germany's BioNTech Vaccine Moderna has the second highly acclaimed vaccine candidate since Pfizer/BioNTech announced theirs a few days ago.  Pfizer claims their vaccine has a more than 90% effective rate. These vaccines have to be approved by regulatory authorities, but their results look very promising and are giving global medical experts hope of quick turnaround depl...

Another $472 Million in Funds from US Government Source:  Moderna Cambridge, MA Potentially Quick Vaccine Development and Delivery Cambridge, MA based Moderna just announced it has received an additional $472 million in funding from the US government's Biomedical Advanced Research and Development Authority (BARDA).  That brings the total from BARDA to support the development of Moderna's novel COVID vaccine to $955 million. mRNA Moderna is the first pharma company in the US to begin human trials on a COVID vaccine.  Tomorrow, July 27th, a Phase 3 study  involving 30,000 participants will get underway with Moderna collaborating with the National Institute of Allergy and Infectious Diseases.  Moderna's vaccine candidate uses synthetic messenger RNA (mRNA) to help the body immunize against the virus. Potential Quick Delivery Moderna says it can deliver 500,000 doses of the vaccine per year and possibly 1 billion doses per year starting in 2021. ...

Closing in on COVID Vaccines Source:  COVID Vaccine R&D EU Historic Stimulus Package Researchers at Oxford University in the UK, along with AstraZeneca, have developed a COVID vaccine that is proving to be successful at building immunity against COVID.  Human trials on more than 1000 patients have proven the vaccine effective.  The vaccine has moved into combined Phase 2 and Phase 3 trials - the last stop to prove it works.  AstraZeneca has a $1.2 billion deal with the US to deliver 300 million doses this fall, if the vaccine is approved. Two More Vaccines Meanwhile, at Moderna Pharma in Cambridge, MA, an experimental mRNA vaccine is in human trials and it is proving to be effective. It has produced antibodies in all the patients involved in the trials And, in China biotech Cansino's vaccine is showing positive antibody responses in a Phase 2 trial.  It is entering Phase 3 trials despite the fact it is not as effective on people over 55 years...

Moderna New Vaccine Goes to National Institutes of Health Source:  Novel Coronavirus Ready for Phase One Human Trials While the deadly Coronavirus continues to take its toll globally, a new vaccine offering hope for prevention is on its way to the NIH in Washington, DC.  This is the first Coronavirus vaccine going into clinical trials by the NIH.  Moderna, a biotech company specializing in vaccines & headquartered in Cambridge, MA, has invented what it calls  the mRNA-1273 vaccine to prevent the Coronavirus infection.  The NIH is going to begin Phase 1 trials for human use.  Turnaround time and availability could be within a year Overnight Share Price Lift Moderna announced that it was shipping the vaccine to the NIH last night.  The company is publicly traded on the NASDAQ.  In overnight trading, Moderna shares were up 15% on the news.  Over the past few years, the company has created more than 100 vaccines and therap...